New findings for IL-6 blockade in the Recovery trial finally confirm a signal. Can pending pandemic readouts for other mechanisms do the same?
But the unveiling of sotorasib’s registrational dataset shows that bulls should be cautious of Mirati's numerical advantage.
The nascent company hopes to prove that its inhaled pan-Jak is best in class.